SETD2 and cancer: As Supplementary Figure 3 showed, by exploring RNAseq data from Genomics of Drug Sensitivity in Cancer (GDSC), we found that half-maximal inhibitory concentration (IC50) of CCSA agents, such as Methotrexate, 5-Fluorouracil (Antimetabolites), Etoposide (Topoisomerase Inhibitors), Bleomycin, Paclitaxel (Plant alkaloids), Cyclophosphamide and Cisplatin for (Alkylating Agents) were higher in samples in which SETD2 expressions are significantly lower, demonstrated that they are more tolerated to these agents.